Sentinel Oncology was founded in 2005 in Cambridge, UK and is a drug discovery company dedicated to the development and commercialisation of new therapeutics to treat patients for whom there is currently an unmet medical need.
The Sentinel Oncology portfolio includes a lead programme that has been licensed to Seattle Genetics Inc. and a second programme which is at the candidate drug phase. We continue to develop a pipeline of novel small drugs to enhance therapeutic index by delivering their effects directly to the tumour.
Sentinel Oncology is a fully integrated drug discovery company seeking to develop high quality drugs andidates for partnering with the pharmaceutical and biotechnology sectors. Our business model is collaborative and we partner with organisations who can maximise the value of our programmes.
If you would like to speak to someone from Sentinel Oncology, please get in touch.